Oxford BioDynamics has completed a clinical trial using EpiSwitchTM technology, to stratify prostate cancer patients with the most aggressive prostate cancer that is at a high risk of spreading from those with less aggressive prostate cancer that can be suitably managed with less invasive treatments.This test will help physicians and patients to make better decisions about the patient’s treatment regime.
News
Jan
Dec
2011
OBD signs research and development agreement with major diagnostic company in Japan
Nov
2011
Professor Jane Mellor publishes article on Epigenetics and Longevity in Phenotype
Nov
2011
$3.2M Rights issue completed underwritten by The Artradis Testudo Fund and Cubana Investment Limited
Oct
2011
OBD Prostate Cancer Clinical Trial Completed
Oct
2011
Notification grant for Singapore patent number 200805949-5
Aug
2011
Notification of grant for New Zealand patent number 571201
Jul
2011
USA diagnostic Company signs EpiSwitch™ development Agreement for Alzheimer’s and Parkinson’s diseases
Jun
2011
Completion of clinical trial for the EpiSwitch™ technology, differentiating Melanoma from Non-Melanoma skin cancers, Basal Cell Carcinoma and Squamous Cell Carcinoma
Oxford BioDynamics has completed a clinical trial using EpiSwitch™ technology, to differentiate Melanoma from Non-Melanoma skin cancers, Basal Cell Carcinoma and Squamous Cell Carcinoma.The technology successfully stratified the cohorts with sensitivity of up to 97% and specificity up to 96%.
Apr
2011
Development agreement signed with Super Religare Laboratory Ltd., India
Mar
2011
Notification of grant for European patent number 07712741.3 (EU)
Nov
2010
Oxford BioDynamics signs development agreement with Singapore Health
Oct
2010
The EpiSwitch™ technology can differentiate the least aggressive from more aggressive prostate cancers
Oxford BioDynamics has completed a test development using the EpiSwitch™ technology, to differentiate the least aggressive cases of prostate cancer from those that are more aggressive. Least aggressive tumours are categorized as Gleason score 4-6 and either Stage I/II or from patients older than 65, whilst more aggressive cases are Gleason grade 7 and above, and either Stage III+ or less than 65 years old. The test can accurately identify the two groups, providing essential information for physicians to determine whether patients require observation or intervention.
Oct
2010
Professor Jane Mellor publishes article on Epigenetics in The Biochemist
Sep
2010
Oxford BioDynamics announces completion results for the EpiSwitch™ Breast Cancer test
Oxford BioDynamics announces completion of the results of the EpiSwitch™ Breast Cancer test on a cohort of 236 samples spanning different grade of cancer, tumour size, lymph node involvement, hormone receptor and HER2 status. The test is based on the platform technology developed on the backdrop of high standards set in ISO 13485:2003, ISO 9001:2008 and FDA 21 CFR Part 820 requirements. The results of the EpiSwitchTM test for diagnosing women with breast cancer show the upper 95% confidence interval of specificity and sensitivity are 98% and 93% respectively.
